Zoetis Reports Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Zoetis (ZTS) PT Lifted to $58 at Piper Jaffray on Solid Q3 and Ahead of Simparica Approval
November 4, 2015 8:52 AM ESTPiper Jaffray analyst Kevin Ellich reiterated an Overweight rating and boosted his price target on Zoetis Inc. (NYSE: ZTS) to $58.00 (from $55.00) following solid Q3 results. The analyst sees Simparica approval coming soon.
Ellich commented, "ZTS' Q3 results were impressive as the company... More
Zoetis (ZTS) Announces 3Q Beat and Raise Along with PHARMAQ Deal; Guggenheim Reiterates Buy
November 3, 2015 1:17 PM ESTGuggenheim reiterated a Buy rating and $60.00 price target on Zoetis Inc. (NYSE: ZTS) following the company's 3Q15 earnings results. ZTS reported 3Q15 EPS of $0.50, $0.10 higher than consensus, and then increased its '15 and '16 EPS guidance to $1.70-$1.74 from $1.63-$1.68 and $1.84-$1.94 from $1.81-$1.93, respectively. The release also included the announcement of a deal with PHARMAQ. Management stated that PHARMAQ... More
Zoetis (ZTS) Tops Q3 EPS by 10c; Issues Solid Outlook
November 3, 2015 7:08 AM ESTZoetis (NYSE: ZTS) reported Q3 EPS of $0.50, $0.10 better than the analyst estimate of $0.40. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.18 billion.
Zoetis sees FY2015 EPS of $1.70-$1.74, versus the consensus of $1.66. Zoetis sees FY2015 revenue of $4.7-4.75 billion, versus the consensus of $4.76 billion.
Zoetis sees FY2016 EPS of $1.84-$1.94, versus the consensus of $1.90. Zoetis sees FY2016 revenue of $4.75-4.875 billion, versus the consensus of $4.76 billion.
Zoetis sees FY2017 EPS of... More
